ReviewClinical and experimental vaccine research2014
Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis.
Review in Clinical and experimental vaccine research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Recombinant BCG-Ag85A enhances antitumor immunity and controls melanoma progression through multimodal immune activation in mice.Archives of microbiology · 2026Article
- A generalizable covalent car-t platform for solid tumors enabled by oncolytic adenovirus-delivered artificial antigens.Frontiers in immunology · 2026Article
- Article
- Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy.Journal of nanobiotechnology · 2024Review
- A Dendritic Cell-Activating Rv1876 Protein Elicits Mycobacterium Bovis BCG-Prime Effect via Th1-Immune Response.Biomolecules · 2021Article
- Fusion of Dendritic Cells Activating Rv2299c Protein Enhances the Protective Immunity of Ag85B-ESAT6 Vaccine Candidate against Tuberculosis.Pathogens (Basel, Switzerland) · 2020Article
- Targeting Autophagy as a Strategy for Developing New Vaccines and Host-Directed Therapeutics Against Mycobacteria.Frontiers in microbiology · 2020Review
- Oxidization of TGFβ-activated kinase by MPT53 is required for immunity to Mycobacterium tuberculosis.Nature microbiology · 2019Article
- Immunization of Vγ2Vδ2 T cells programs sustained effector memory responses that control tuberculosis in nonhuman primates.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- EXPRESSION OF IMMUNOGLOBULIN, GRANZYME-B AND PERFORIN AGAINST Ag85A AND Ag85B PROTEINS OF MYCOBACTERIUM TUBERCULOSIS IN BALB/C MICE.African journal of infectious diseases · 2019Article
- Article
- Next generation sequencing reveals changes of the γδ T cell receptor repertoires in patients with pulmonary tuberculosis.Scientific reports · 2018Article
- Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review.Iranian journal of basic medical sciences · 2018Review
- Striking the right immunological balance prevents progression of tuberculosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- Adoptive Transfer of Phosphoantigen-Specific γδ T Cell Subset AttenuatesJournal of immunology (Baltimore, Md. : 1950) · 2017Article
- Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.Human vaccines & immunotherapeutics · 2017Article
- Article
- Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K.Scientific reports · 2017Article
- Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses.Vaccines · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a worldwide health problem, causing around 2 million deaths per year. Despite the bacillus Calmette Guérin vaccine being available for more than 80 years, it has limited effectiveness in preventing TB, with inconsistent results in trials. This highlights the urgent need to develop an improved TB vaccine, based on a better understanding of host-pathogen interactions and immune responses during mycobacterial infection. Recent studies have revealed a potential role for autophagy, an intracellular homeostatic process, in vaccine development against TB, through enhanced immune activation. This review attempts to understand the host innate immune responses induced by a variety of protein antigens from Mycobacterium tuberculosis, and to identify future vaccine candidates against TB. We focus on recent advances in vaccine development strategies, through identification of new TB antigens using a variety of innovative tools. A new understanding of the host-pathogen relationship, and the usefulness of mycobacterial antigens as novel vaccine candidates, will contribute to the design of the next generation of vaccines, and to improving the host protective immune responses while limiting immunopathology during M. tuberculosis infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.